Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer

Abstract

The aim of this study was to assess the potential effects of palbociclib in combination with letrozole on QTc. PALOMA-2, a phase 3, randomized, double-blind, placebo-controlled trial, compared palbociclib plus letrozole with placebo plus letrozole in postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative… (More)
DOI: 10.1097/CAD.0000000000000589

5 Figures and Tables

Topics

  • Presentations referencing similar topics